Contributing factors to heparin resistance during cardiopulmonary bypass

被引:1
作者
Yamashiro, Tomoaki [1 ]
Takami, Yoshiyuki [2 ]
Takagi, Yasushi [2 ]
机构
[1] Fujita Hlth Univ Hosp, Dept Clin Engn, 1-98 Dengakugakubo, Toyoake, Aichi 4701192, Japan
[2] Fujita Hlth Univ, Dept Cardiovasc Surg, Sch Med, 1-98 Dengakugakubo, Toyoake, Aichi 4701192, Japan
关键词
Heparin resistance; Cardiopulmonary bypass; Activated clotting time; Unfractionated heparin; DOSE-RESPONSE; INHIBITION; ANTITHROMBIN; EFFICACY; THROMBIN; AFFINITY; ALBUMIN; THERAPY; BINDING; FIBRIN;
D O I
10.1007/s10047-024-01435-1
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Since the risk factors for heparin resistance (HR) before cardiopulmonary bypass (CPB) have not been fully clarified, this study investigated the contributing factors for HR after the initial unfractionated heparin (UFH) dose of 500 IU/kg. We retrospectively analyzed the data of 371 patients who underwent CPB surgery, with the initial UFH dose of 500 IU/kg, between May 2017 and December 2021. We defined HR as the failure to achieve activated clotting time (ACT) of > 480 s after the initial UFH dose of 500 IU/kg. HR was observed in 36 patients (9.7%) (HR group), while HR was not observed in 335 patients (control group). The HR group included significantly more patients with preoperative use of UFH, with significantly higher white blood cell counts, fibrinogen, fibrinogen degradation products, d-dimer, and C-reactive protein, and lower hemoglobin and albumin. The multivariable logistic regression analysis identified albumin (OR: 3.09, 95% CI 1.3504-7.0845, p = 0.0075) and fibrinogen (OR: 0.99, 95% CI 0.9869-0.9963, p = 0.0003) as independent predictors for HR. Using the Youden index, the cutoffs of albumin and fibrinogen were calculated as 3.8 g/dL and 303 mg/dL, respectively. The receiver operating characteristic curves showed the predictive performance of albumin (area under the curve (AUC): 0.78, sensitivity: 65%, specificity: 81%) and fibrinogen (AUC: 0.77, sensitivity: 56%, specificity: 88%). The incidence of HR after the initial UFH dose of 500 IU/kg was 9.7%. The preoperative albumin < 3.8 g/dL and fibrinogen > 303 mg/dL were independent predictors for HR.
引用
收藏
页码:385 / 392
页数:8
相关论文
共 50 条
  • [41] Protective effect of heparin-coated circuits on the platelets during cardiopulmonary bypass
    Zhang Kailun
    Hu Zhiwei
    Yang Yunhai
    Huang Ruqing
    Fan Huiming
    Sun Zongquan
    Current Medical Science, 2003, 23 (4) : 403 - 406
  • [42] Identifying optimal heparin management during cardiopulmonary bypass in obese patients: A prospective observational comparative study
    Haas, Emmanuel
    Fischer, Francois
    Levy, Francois
    Degirmenci, Su-Emmanuelle
    Grunebaum, Lelia
    Kindo, Michel
    Collange, Olivier
    Mertes, Paul-Michel
    Steib, Annick
    EUROPEAN JOURNAL OF ANAESTHESIOLOGY, 2016, 33 (06) : 408 - 416
  • [43] Identifying optimal heparin management during cardiopulmonary bypass in Chinese people: a retrospective observational comparative study
    Gan, Yongbo
    Yang, Zhijian
    Mei, Wei
    Zhu, Chang
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2020, 49 (03) : 480 - 486
  • [44] Bivalirudin for cardiopulmonary bypass in a patient with heparin allergy
    Boysan, Emre
    Circi, Renda
    Beyazal, Osman Fehmi
    Sener, Erol
    JOURNAL OF CARDIOTHORACIC SURGERY, 2023, 18 (01)
  • [45] Con: Heparin is not the best anticoagulant for cardiopulmonary bypass
    Fitch, JCK
    JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 1996, 10 (06) : 819 - 821
  • [46] Intravenous heparin for cardiopulmonary bypass is an acute vasodilator
    Jacka, MJ
    Clark, AG
    JOURNAL OF CLINICAL ANESTHESIA, 2002, 14 (03) : 179 - 182
  • [47] Bivalirudin for cardiopulmonary bypass in a patient with heparin allergy
    Emre Boysan
    Renda Circi
    Osman Fehmi Beyazal
    Erol Şener
    Journal of Cardiothoracic Surgery, 18
  • [48] Pro: Heparin is the best anticoagulant for cardiopulmonary bypass
    Rinder, CS
    JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 1996, 10 (06) : 816 - 818
  • [49] Anticoagulation for cardiopulmonary bypass of a patient with ''heparin allergy''
    Ochroch, E
    Shorten, GD
    Rvaula, RE
    Comunale, ME
    JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 1997, 11 (05) : 622 - 624
  • [50] Factors associated with errors in the heparin dose response test: recommendations to improve individualized heparin management in cardiopulmonary bypass
    Lee, Min-Ho
    Riley, William
    PERFUSION-UK, 2021, 36 (05): : 513 - 523